<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061109</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ-NXBYZ-02</org_study_id>
    <nct_id>NCT04061109</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.</brief_title>
  <official_title>Multicenter, Noncontrol Study of Recombinant Coagulation Factor VIII for Prophylactic Therapy in Subjects With Hemophilia A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, single-arm trial to evaluate the efficacy and safety of
      Recombinant Coagulation Factor VIII in patients with hemophilia A . Recombinant Coagulation
      Factor VIII is prophylactic administrated 25 - 35 IU/kg once every other day or three times
      per week which should be continuous for 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized joint bleeding rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Annualized joint bleeding rate（AJBR） can be calculated using the following formula: Number of joint bleeding events during efficacy evaluation period/(number of days in treatment period/365.25).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental Recovery of the First Dose</measure>
    <time_frame>After the first dose on day 1</time_frame>
    <description>Peak activity of FVIII (as Cmax) measured within 1 hour after the end of injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Event Treatment Efficacy</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly Average Number of Bleedings</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Number of bleeding events in each month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and dose of injection of Recombinant Human Coagulation FVIII required per bleeding episode</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The number and dose of injection of Recombinant Human Coagulation FVIII required per bleeding episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery of Duplicated Dose</measure>
    <time_frame>up to 12 weeks, 24 weeks</time_frame>
    <description>Peak activity of FVIII (as Cmax) measured within 1 hour after the end of injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemophilia Joint Health Score (HJHS)</measure>
    <time_frame>Baseline, week 24</time_frame>
    <description>The scale assesses the functional status of the six major joints of the elbow, knee, and ankle, including: joint swelling, swelling duration, muscle atrophy, muscle strength, joint friction, joint pain, joint extension, joint flexion Degree decline, overall gait, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of Recombinant Human Coagulation FVIII following Patient Reported Outcome (PRO) EQ-5D</measure>
    <time_frame>Baseline, week 24</time_frame>
    <description>EQ-5D is a general questionnaire designed to measure health status on a scale of 0-100 with the higher value representing a better outcome and record the participants' current health state in 5 domains mobility, selfcare, usual activities, pain, anxiety.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Prophylactic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Recombinant Human Coagulation FVIII for prophylactic therapy with 25 - 35 IU/kg injection once every other day or three times per week for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Coagulation FVIII</intervention_name>
    <description>A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.</description>
    <arm_group_label>Prophylactic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hemophilia A.

          2. FVIII:C &lt;1%. 3）12 and 65 years old.

        4）Has received FVIII treatment and the treatment exposure days ≥100. 5）Has bleeding
        treatment records of at least 3 months before randomization. 6）FVIII inhibitor assay
        results is negative. 7） Subjects should agree to use an adequate method of contraception
        during the study.

        8）Understood and Signed an informed consent form.

        Exclusion Criteria:

          1. Has a history or family history of blood coagulation factor VIII inhibitor.

          2. Has other coagulation dysfunction diseases in addition to hemophilia A.

          3. HIV positive.

          4. Plan to receive surgery during the trial.

          5. Has used immunomodulator within one weeks before the first dose，and less than 7
             half-life periods.

          6. Known to be allergic to experimental drugs or any excipients.

          7. Severe anemia and need blood transfusion.

          8. Serious liver or kidney damage.

          9. Serious heart disease.

         10. Uncontrollable hypertension.

         11. Has participated in other clinical studies within one month before the first dose.

         12. The researchers believe that it is not suitable for participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Zhang, Doctor</last_name>
    <phone>022-20909240</phone>
    <email>zhanglei1@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>AnHui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zimin Sun, Doctor</last_name>
      <phone>0551 -62283191</phone>
      <email>zmsun_vip@163.com</email>
    </contact>
    <investigator>
      <last_name>Zimin Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shifeng Lou, Master</last_name>
      <phone>023-62887783</phone>
      <email>13508331213@163.com</email>
    </contact>
    <investigator>
      <last_name>Shifeng Lou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FuJian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meijuan Huang, D</last_name>
      <phone>0591-86218041</phone>
      <email>huangmj163@163.com</email>
    </contact>
    <investigator>
      <last_name>Meijuan Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of LanZhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaming Xi, Doctor</last_name>
      <phone>0931-8356266</phone>
      <email>xiyaming@163.com</email>
    </contact>
    <investigator>
      <last_name>Yaming Xi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Cheng, Master</last_name>
      <phone>0771-12580</phone>
      <email>13977166448@163.com</email>
    </contact>
    <investigator>
      <last_name>Peng Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HeNan Provincial Peoples Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Wang, Doctor</last_name>
      <phone>0371-65896920</phone>
      <email>jenny1983218@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhen Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HeNan Cancer Provincial Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hu Zhou, Doctor</last_name>
      <phone>0371-65587278</phone>
      <email>papertigerhu@163.com</email>
    </contact>
    <investigator>
      <last_name>Hu Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xielan Zhao, Doctor</last_name>
      <phone>0731-84327564</phone>
      <email>zhaoxl9198@163.com</email>
    </contact>
    <investigator>
      <last_name>Xielan Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongfu Zhou, Doctor</last_name>
      <phone>83106666-61441</phone>
      <email>rfzhoucn@163.com</email>
    </contact>
    <investigator>
      <last_name>Rongfu Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenghao Jin, Doctor</last_name>
      <phone>0791-86895612</phone>
      <email>Jinch227@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Chenghao Jin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Zhang, Doctor</last_name>
      <phone>022-20909240</phone>
      <email>zhanglei1@ihcams.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Lei Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

